Leaderboards/PD-1/PD-L1

PD-1/PD-L1

Last updated June 1, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Thomas Yau
Queen Mary Hospital
89
2
Lawrence Fong
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
85
3
Xuelei Ma
Sichuan University
82
4
Caicun Zhou
Tongji University
81
5
Runxiang Yang
Yunnan Machinery Research and Design Institute
81
6
Dean F. Bajorin
Memorial Sloan Kettering Cancer Center
75
7
Caitlin C. Zebley
St. Jude Children's Research Hospital
68
8
Douglas Adkins
Barnes-Jewish Hospital
67
9
Lu Zheng
First Affiliated Hospital of Zhengzhou University
63
10
Hai Wang
National Center for Nanoscience and Technology
56

Rising Stars Papers

1
Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment
Experimental Hematology and Oncology|2024
29 cit.

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Ravindra Uppaluri
Brigham and Women's Hospital
99
2
Jean Bourhis
University Hospital of Lausanne
95
3
Michael K. Wong
Roswell Park Comprehensive Cancer Center
81
4
Jeffrey D. Bradley
University of Pennsylvania
76
5
Dian Xiao
National Medical Products Administration
74
6
Anuj Patel
Harvard University
70
7
María Gión
Hospital Universitario Ramón y Cajal
68
8
Dan P. Zandberg
University of Pittsburgh
64
9
Martin Wermke
Nationales Centrum für Tumorerkrankungen Dresden
64
10
Benjamin Levy
Johns Hopkins University
62

Emerging Leaders Papers

Insufficient data

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Thomas Powles
Queen Mary University of London
99
2
Edward B. Garon
University of California, Los Angeles
85
3
David R. Gandara
University of California, Davis
82
4
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
78
5
Robert Dreicer
University of Virginia
74
6
David R. Kaufman
Merck & Co., Inc., Rahway, NJ, USA (United States)
73
7
Marina Chiara Garassino
Fondazione IRCCS Istituto Nazionale dei Tumori
71
8
James Larkin
Royal Marsden NHS Foundation Trust
70
9
Julie R. Brahmer
LungenClinic Grosshansdorf
70
10
F. Stephen Hodi
Dana-Farber Cancer Institute
70

All-Time Leaders Papers

1
Pembrolizumab versus Ipilimumab in Advanced Melanoma
New England Journal of Medicine|2015
5.8k cit.
2
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
New England Journal of Medicine|2019
3.7k cit.
3
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
New England Journal of Medicine|2016
3.1k cit.
4
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Nature|2010
2.5k cit.
5
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
New England Journal of Medicine|2014
2k cit.
6
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Cell Reports|2017
1.9k cit.
7
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Journal of Clinical Oncology|2015
1.2k cit.
8
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
JAMA|2016
1.1k cit.
9
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
Journal of Clinical Oncology|2013
813 cit.
10
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Journal for ImmunoTherapy of Cancer|2021
804 cit.

Indexing PD-1/PD-L1 Reagents

Citation data for reagents in this field is currently compiling.